TMPRSS2 and viral infectious disease: Unlike pre-treatment with furin, TMPRSS2, or trypsin, all of which increased VSV-SARS-CoV-2 infection at low doses, pre-treatment with FXa reduced viral infection regardless of the dose (Supplementary Fig. 3a–c).